Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045249 | 0.97 | RAB9A (0.44) | PTGDRNPC1RAB9AGALR3NR2F2 | |
| SCHEMBL5432174 | 0.91 | RAB9A (0.50) | PTGDRNPC1RAB9AGALR3NR2F2 | |
| SCHEMBL31045078 | 0.89 | KCNH2 (0.40) | PTGDRNPC1RAB9AGALR3NR2F2 | |
| SCHEMBL31044704 | 0.89 | TRIM58 (0.40) | NPC1RAB9AGALR3NR2F2ACP1 | |
| SCHEMBL31044664 | 0.88 | NPC1 (0.37) | NPC1RAB9AGALR3NR2F2MEN1 | |
| SCHEMBL31044903 | 0.88 | PRKCI (0.44) | NPC1RAB9AGALR3NR2F2ACP1 | |
| SCHEMBL31044877 | 0.88 | ALDH1A1 (0.40) | NPC1RAB9AGALR3NR2F2MEN1 | |
| SCHEMBL31044841 | 0.88 | NPC1 (0.35) | PTGDRNPC1RAB9AGALR3NR2F2 | |
| SCHEMBL31045439 | 0.86 | NPC1 (0.40) | NPC1RAB9AGALR3NR2F2 | |
| SCHEMBL31044752 | 0.86 | NFKB1 (0.40) | PTGDRNPC1RAB9AGALR3NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | PTGDR 1915/4885NPC1 626/4885RAB9A 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.